USFDA conducts inspection at Zydus group’s Unit-2 manufacturing plant at Ankleshwar
The company will closely work with the USFDA to address the observations expeditiously
United States Food and Drug Administration (USFDA) has conducted an inspection at the Zydus group’s Unit-2 manufacturing plant at Ankleshwar, Gujarat. The inspection was conducted from January 19, 2026 to January 23, 2026 and concluded with 3 observations. There were no data integrity related observations. The company will closely work with the USFDA to address the observations expeditiously.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
